Regenicin, Inc. Share Price

Equities

RGIN

US75887Q1022

Biotechnology & Medical Research

Market Closed - OTC Markets 07:46:10 11/04/2024 pm IST 5-day change 1st Jan Change
0.005 USD +4,900.00% Intraday chart for Regenicin, Inc. 0.00% +4,99,900.00%
Sales 2021 - Sales 2022 - Capitalization 491K 40.96M
Net income 2021 - 0 Net income 2022 - 0 EV / Sales 2021 -
Net Debt 2021 598K 49.9M Net Debt 2022 627K 52.32M EV / Sales 2022 -
P/E ratio 2021
-2 x
P/E ratio 2022
-0.71 x
Employees 3
Yield 2021 *
-
Yield 2022
-
Free-Float 79.1%
More Fundamentals * Assessed data
Dynamic Chart
Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022 CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021 CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021 CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021 CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021 CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020 CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020 CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020 CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019 CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019 CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2019 CI
More news
1 day+4,900.00%
Current month+4,900.00%
1 month+4,900.00%
6 months+900.00%
More quotes
1 month
0.00
Extreme 0.0001
0.01
Current year
0.00
Extreme 0.0001
0.01
1 year
0.00
Extreme 0
0.01
3 years
0.00
Extreme 0
0.04
5 years
0.00
Extreme 0
0.04
10 years
0.00
Extreme 0
0.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 74 15/10/15
Director of Finance/CFO 74 13/10/13
Chief Tech/Sci/R&D Officer 75 15/10/15
Members of the board TitleAgeSince
Director of Finance/CFO 74 13/10/13
Chief Executive Officer 74 15/10/15
More insiders
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.
More about the company